APOM and chronic kidney disease: Here, we demonstrate that reduced plasma levels of APOM are associated with an increased risk of MACE in patients with CKD, independent of traditional cardiovascular and renal risk factors in the CARE FOR HOMe study, a well-characterized cohort with many years of follow-up, and a large number of recorded events.